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Background: The prognosis for pancreatic cancer (PC) is very poor. The SnoN gene may have a role in cell
proliferation and apoptosis in human cancer. However, the influence of SnoN on cell proliferation and apoptosis in
human PC cells remains unknown.
Methods: SnoN expression was assessed in SW1990 PC cell lines using real-time polymerase chain reaction (PCR).
A luciferase reporter assay was used to confirm the target associations. The effect of SnoN on cell proliferation
in vitro was confirmed using Cell Counting Kit-8. Apoptosis was confirmed using flow cytometry. Gene and
protein expression were examined using real time PCR and Western blotting, respectively.
Results: SnoN siRNA significantly inhibited the growth of SW1990 cells by decreasing cell proliferation (P < 0.05)
and increasing cell apoptosis (P < 0.05), compared with the blank group and the negative control group. The
highest inhibition of cell proliferation appeared at 3 days post-transfection. Cell apoptosis more obvious at 48 h
after transfection.
Conclusions: In summary, our results reveal that the RNAi-mediated downregulation of SnoN effectively inhibited
the proliferation of PC cells. SnoN-siRNA also enhanced SW1990 PC cell apoptosis. These findings indicate that
SnoN gene plays an important role in pancreatic cancer development, and might serve as a potential therapeutic
target for pancreatic cancer. However, further in vivo studies are needed to clarify the influence of SnoN gene
silencing by siRNA on pancreatic cancer therapy.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/7609324661510147
Keywords: SnoN gene, Proliferation, Apoptosis, Pancreatic cancer (PC)Background
Pancreatic cancer (PC) is one of the most fatal malig-
nant diseases worldwide. The incidence of PC is lower
than that of many other types of cancer. However, it is
the fourth most common cause of death from cancer
[1]. Because of nonspecific incipient symptoms and early
metastasis, PC is highly malignant and invasive, resulting
in poor prognosis [2]. Previous statistics for 2002–2008
from the US National Cancer Institute showed an overall
5-year relative survival rate of 5.8% and a one-year* Correspondence: chengllbj@163.com
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unless otherwise stated.mortality rate of 90%, with a median survival of less than
6 months [3,4].
A number of studies [5-8] have showed that the devel-
opment and progression of PC are linked with complex
gene regulation, such as the inactivation of tumour sup-
pressor genes, the activation of proto-oncogenes, abnormal
regulation of cell proliferation and apoptosis adjustment
disorders, and abnormal expression of growth factors and
their receptors. In recent years, although targeted therapies
in PC treatment have been gradually developed, the PC sur-
vival rate has not improved. Therefore, there is an urgent
need for the identification of possible associated factors and
novel therapeutic targets for PC.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oncogenes that was originally identified based on se-
quence homology with v-Ski, encodes an oncoprotein
that can induce anchorage-independent growth of
chicken and quail embryo fibroblasts when overex-
pressed [9-12]. SnoN is highly expressed in human can-
cer cells of the oesophagus, lung, vulva, stomach, ovary,
pancreas, and breast [10,13-15]. SnoN overexpression in
human cancer cells may result in gene amplification,
transcriptional activation, and increased protein stability
[14,16-19]. Moreover, SnoN was recently shown to si-
lence the alpha fetoprotein gene, cooperating with p53
to negatively regulate transforming growth factor beta
(TGF-β) signalling [19-21]. Although several previous
studies investigated the effects of SnoN on the cell prolif-
eration and apoptosis of ovarian, lung, breast, oesopha-
geal, and colon cancers [22-26], the role SnoN plays in
pancreatic cancer remain unknown.
In the present study, we established a pancreatic can-
cer cell line that stably silenced the SnoN gene by
siRNA, and investigated the effects of SnoN on the pro-
liferation and apoptosis of pancreatic cancer cells
in vitro. This study may provide experimental evidence
for gene therapy in PC.
Methods
Ethical approval
This study was approved by the Ethics Committee of Air
Force General Hospital of PLA.
Cell culture
The SW1990 human pancreatic cancer cells were ob-
tained from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM, HyClone, Logan, UT,
USA) supplemented with 10% foetal bovine serum (FBS,
HyClone, Logan, UT, USA), 100 U/mL penicillin and
100 μg/mL streptomycin. Cells were maintained in a 37°C
humidified incubator containing 95% air and 5% CO2.
Reagents
Opti-MEM medium and Lipofectamine 2000 (Lipo)
were obtained from the Gibco-Invitrogen Corporation
(USA). Trypsin was obtained from the HyClone Corpor-
ation (USA). The β-actin mAb was purchased from the
Shanghai Kangcheng Biotechnology Corporation (Shanghai,
China). The SnoN mAb was purchased from the Abcam
Corporation (UK). The cDNA synthesis kit and TRIzol kit
were purchased from Bao Biotechnology Corporation
(Dalian, China). The RNA PCR kit was obtained from
TaKaRa Corporation (Japan). The Western Blotting De-
tection system was obtained from Thermo Corporation
(USA). The cell lysate and bicinchoninic acid (BCA) pro-
tein assay kit was purchased from Shanghai BiyuntianBiotechnology Corporation (Shanghai, China). The Cell
Counting Kit-8 was obtained from Dojindo Chemical Cor-
poration (CCK-8, Japan). The Annexin V FITC/PI assay
kit was purchased from Invitrogen Corporation (USA).
SnoN siRNA sequences and PCR primers
SnoN siRNAs, labelled by florescence FAM (FAM-siRNAs),
and negative control siRNAs were synthesised by Shanghai
Jima Biotechnology Co., Ltd. (Shanghai, China). For the
SnoN siRNA-A, the sense strand was 5’-GGGCUUUG
AAUCAGCUAAATT-3’ and the antisense strand was 5’-U
UUAGCUGAUUCAAAGCCCTT-3’. For the SnoN siRNA-
B, the sense strand was 5’-GGCCCAGUUAAAGGAAAC
UTT-3’ and the antisense strand was 5’-AGUUUCCU
UUAACUGGGCCTT-3’. For the SnoN siRNA-C, the sense
strand was 5’-GAGGCAAGUAAGUCCAUAUTT-4’ and
the antisense strand was 5’-AUAUGGACUUACUUGCC
UCTT-3’. For the negative control siRNA, the sense strand
was 5’-UUCUCCGAACGUGUCACGUTT-3’ and the anti-
sense strand was 5’-ACGUGACACGUUCGGAGAATT-3’.
The SnoN primers were forward, 5’-AGAGACTCTGTT
TGCCCCAAGT-3’ and reverse, 5’-CATGCTAAACTTCT
CCTTCATTTC-3’. The β-actin primers were forward, 5’-T
TCTGTGGCATCCACGAAACT-3’ and reverse, 5’-GAAG
CATTTGCGGTGGACGAT-3’.
siRNA transfection
The pancreatic cancer cells were seeded at 1×105 cells/
well in 24-well plates 1 day before transfection. Medium
without antibiotics was added to each well so that the
cells grew to 50-70% confluence, when the transfection
was conducted. The siRNA-Lipo mixture was prepared
according to the manufacturer's instructions. To test the
transfection efficiency of the FAM-siRNAs-Lipo mixture
at different concentrations, 0, 1, 1.5 and 2 μl of Lipo
were diluted with 50 μl Opti-MEM, and 0, 10, 15 and
20 μl FAM-siRNAs, respectively, were added at 50 μl/
well and mixed. The 100 μl mixture was added to 300 μl
of Opti-MEM including the pancreatic cancer cells. The
concentrations of the four groups were 0 nmol/L,
50 nmol/L, 75 nmol/L, and 100 nmol/L, respectively. Six
hours later, the medium was replaced with DMEM sup-
plemented with 10% FBS. The expression of FAM-
siRNAs was analysed with a flow cytometer.
Quantitative RT-PCR
Total RNA was extracted from cells using TRIzol reagent
and reverse transcribed to cDNA using a first-strand
cDNA synthesis kit according to the manufacturer’s in-
structions. The efficiency of the SnoN siRNAs was
screened using RT-PCR and real-time PCR. Real-time
PCR was conducted on the Exicycler™ 96 florescence
quantitative instrument (Bioneer, Daejeon, Korea). PCR
Figure 1 Expression of SnoN mRNA in SW1990 cells. A The effect of
three different siRNA sequences on silencing the expression of SnoN
mRNA in SW1990 cells. B Real-time PCR was used to detect the
SnoN mRNA expression level. #P >0.05 and *P < 0.05, compared with
the blank control group.
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published methods [27].
Western blotting
SnoN protein expression was measured by Western blot-
ting. β-actin was used as an internal control. Cells were
lysed using cell lysis buffer, and the protein concentrations
were quantified using the BCA assay method. Cellular
proteins were dissolved in sample loading buffer and run
on 7.5% sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels (100 V, constant voltage,
60 min). SnoN protein was electrotransferred onto PVDF
membranes (4°C, 280 mA, 60 min). The membranes were
rinsed with PBS and blocked with 10% non-fat milk in
PBS for 2 h at room temperature. Primary antibody was
used at the following dilutions. After primary antibody in-
cubation, membranes were rinsed in TBS-T wash buffer 3
times for 10 min each. Then, secondary antibody (1:
2,000) was incubated for 2 h at room temperature and
rinsed in TBS-T wash buffer 3 times for 10 min each. De-
veloped films were digitised by scanning, and the optical
densities were analysed with the image software.
Cell proliferation analysis
Cell viability was measured using the CCK-8 assay. Cells
were seeded into 96-well plates at a density of 3 × 103
cells/well and placed in an incubator until the cells grew
to confluence. Subsequently, 100 μl of CCK-8 solution
was added at different time points (0, 24, 48, 72, and
96 h), and the samples were incubated at 37°C for 1.5 h.
The absorbance value of each well was measured at
450 nm using a microplate reader. Non-transfected cells
were set as the blank control group. Cells treated with
negative siRNA transfection were set as the negative
control group.
Analysis of cell apoptosis
An annexin V FITC/PI assay kit was used to detect cell
apoptosis. Cells were divided into three groups (blank
control group, negative control group, and transfection
group). At 50% - 70% confluence, the cells were trypsi-
nised and collected. After washing with PBS, 500 μl of
annexin-binding buffer was added to resuspend the cells.
After the addition of 5 μl Alexa-labelled annexin V and
1 μl PI, the cells were incubated at room temperature in
the dark for 15 min and then detected by flow cytometry.
Statistical analysis
Data are presented as the mean ± standard deviation
and were analysed using one-way analysis of variance
(ANOVA) between groups using the SPSS 16.0 soft-
ware. The differences among multiple mean values
were evaluated using ANOVA. The differences between
two mean values were estimated using an independent-samples t-test. The differences among the groups were




The transfection efficiency was measured by flow cytome-
try. When the concentrations of the FAM-siRNA mixture
were 0 nmol/L, 50 nmol/L, 75 nmol/L, and 100 nmol/L,
the transfection efficiencies were 9.38%, 29.9%, 57.4%, and
87.5%, respectively. We found that the optimal transfec-
tion concentration was 100 nmol/L.
Silencing efficiency of SnoN siRNAs
Three SnoN siRNA sequences were used to determine
the silencing efficiency on SnoN mRNA expression in
pancreatic cancer cells. The results after real-time PCR
analysis showed little difference in band brightness be-
tween the five β-actin groups, which revealed that the
RNA template for reverse transcription was equal in
each group. No significant difference was observed be-
tween the blank and negative control groups. However,
lower band brightness was evident in the three siRNA
groups, compared with the blank or negative control
groups (P < 0.05). According to the ratio of the optical
density values between the SnoN and β-actin bands,
similar results were observed. The SnoN siRNA-C was
found to have the most powerful silencing effect on the
SnoN gene (Figure 1).
Figure 3 The CCK-8 method was used to detect cell proliferation.
Cells were seeded in 96-well plates, and the absorbance of each well
was detected at different time points at 450 nm, n = 6.
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Western blotting
The pooled results demonstrated that protein expression
decreased in the three siRNA groups compared with the
blank or negative control groups (P < 0.05). SnoN
siRNA-C had the most powerful inhibitory effect on
SnoN protein expression (Figure 2).
The effect of silencing SnoN on cell proliferation
The growth curve representing cell proliferation was
drawn according to the results of the CCK-8 assay. The
SnoN siRNA-C group was significantly decreased at each
day after transfection (P < 0.05). The lowest cell viability
was observed at 3d after transfection, and the recovery
of cell viability started at 4d after transfection (Figure 3).
The effect of silencing SnoN on cell apoptosis
The apoptotic cells increased after pancreatic cancer
cells were transfected with SnoN siRNA-C (P < 0.05).
This was more obvious at 48 h after transfection. There
was a significant difference between the SnoN siRNA
group and the negative control group (P < 0.05). There
was a significant difference between the SnoN siRNA
group and the blank control group (P < 0.05). Moreover,Figure 2 Expression of SnoN protein in transfected SW1990 cells.
A Western blotting was used to detect the cyclin SnoN protein
expression level in each group. Representative results obtained from
three repeated experiments are presented in the figure. B β-actin
was used as an internal reference to analyze the relative protein
expression level of cyclin SnoN, n = 3. #P >0.05 and *P < 0.05,
compared with the blank control group.there were no significant differences between the nega-
tive control group (negative siRNA transfected cells)
and the blank control group (non-transfected cells)
(Figure 4, Table 1).Discussion
The present work provides evidence of the importance
of SnoN for cell growth in MPM. The transient SnoN-
silencing caused a decrease in the proliferation rate of
the pancreatic cancer cell line and an increase in the
apoptosis rate.
Fewer than 5% of patients with PC achieve 5-year sur-
vival, which reveals the poor prognosis of this cancer
[28]. Therefore, to improve modern cancer therapy, nu-
merous scholars have an ongoing interest in the identifi-
cation of signalling pathways and genes that might play
key roles in carcinogenesis and the development of re-
sistance to anti-tumour drugs, with the hope of identify-
ing putative biomarkers and/or therapeutic targets
[29,30]. Applying molecular approaches, a large set of
genes has been investigated for overexpression in pan-
creatic cancer [31-33]. However, more genes that may
have an effect in the progression of PC need to be
investigated.
The human SnoN gene is located at chromosome
3q26.2. SnoN is widely expressed in adult and embryonic
cells. SnoN expression can be regulated at the level of
gene amplification, transcriptional activation and protein
stability. High expression of SnoN is found in many hu-
man cancers [22-26]. However, not all studies were con-
sistent with upregulated SnoN expression in human
cancers. While some studies reported an increase in
SnoN RNA and protein in some cancer tissues and
noted that this higher SnoN expression correlated with
poor differentiation, deeper invasion and poor patient
survival [14,15,25], others detected a decrease in SnoN
Figure 4 The effect of SnoN siRNA-C on apoptosis of SW1990 cells was tested by FCM.
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and highly invasive cancers [34-36]. It appears that SnoN
can also act as a negative regulator of tumour progres-
sion. In a recent study [21], SnoN was observed to
cooperate with p53 in the silencing of the alpha fetopro-
tein gene, which is aberrantly overexpressed in liver can-
cer cells.
Moreover, SnoN and its structurally and functionally
related protein Ski are negative regulators of TGF-β-
induced transcription [37]. The level of SnoN is dir-
ectly linked to its ability to repress TGF-β signalling,
but this activity may be cell-type specific [38]. SnoN
has been reported to be both a tumour promoter and
a tumour suppressor [39]. Over-expression of SnoN
leads to resistance to TGF-β-induced growth arrest
and formation of mammary tumours in cooperation
with polyoma middle T-antigen [17]. Furthermore, pre-
vious studies have shown that SnoN interacts directlyTable 1 The effect of SnoN-siRNA on apoptosis of PC cells
(n = 3)
Group Time (d) Apoptosis (%)
Blank control 24 0.26 ± 0.27
48 0.67 ± 1.38
72 1.77 ± 1.54
Negative control 24 0.29 ± 0.31
48 0.72 ± 1.15
72 2.13 ± 1.97
SnoN-siRNA-C 24 0.56 ± 0.29*
48 6.94 ± 2.17*
72 7.45 ± 2.01*
*P < 0.05 vs. blank control.with Smad2, Smad3, and Smad4 and represses their
ability to activate expression of TGF-β target genes by
disrupting the formation of an active heteromeric Smad
complex, recruiting a transcriptional corepressor com-
plex, and by blocking the interaction of transcriptional
coactivators with Smad2 and Smad3 [40,41]. A number
of investigations have indicated that PC is closely asso-
ciated with the TGF-β/Smad pathway, and Smad4 is
inactivated in nearly 60% of PC [42]. However, the in-
fluence of SnoN gene expression on cell proliferation
and apoptosis in human pancreatic cancer cells remains
unclear.
Cell proliferation and apoptosis are important to the
oncogenesis and chemotherapy resistance of pancreatic
cancer cells [8]. In this study, we analysed the suppressive
effect of PC cell proliferation and apoptosis by siRNA si-
lencing of SnoN expression. The results showed that the
proliferation of the SnoN-siRNA-transfected cells was
slower than blank and negative group, suggesting a funda-
mental role for SnoN in the development of PC. There-
fore, through silencing SnoN gene, development of PC
might be alleviated. To date, this is the first study in which
RNAi-mediated SnoN expression was shown to inhibit PC
cell proliferation and induce apoptosis. This finding is
consistent with the previous results that SnoN promotes
tumour proliferation and induces apoptosis in other can-
cers [14,15,25]. However, because the exact effect of SnoN
expression on human cancers remains unclear, and mul-
tiple signalling pathways are thought to make important
contributions to PC progression, further studies are neces-
sary to clarify these complex mechanisms. Moreover, our
study has a limitation, in that we only proved that RNAi
inhibited SnoN expression in vitro. Therefore, further
in vivo studies are needed to verify the effect and risk of
SnoN knockdown by SnoN-siRNAs for PC therapy.
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In summary, our results revealed that the RNAi-mediated
downregulation of SnoN effectively inhibited the prolifera-
tion of PC cells. Meanwhile, SnoN-siRNA also enhanced
PC cell apoptosis. These findings indicated that SnoN plays
an important role in pancreatic cancer development, and
might serve as a potential therapeutic target for pancreatic
cancer. However, further in vivo studies are needed to clar-
ify the influence of SnoN gene silencing by siRNA on pan-
creatic cancer therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CLL performed the literature search, collected the data and drafted the
manuscript. HZ, XXZ and CW performed the database setup and statistical
analysis. YLK and HYZ helped to draft the manuscript. All authors have read
and approved the final manuscript.
Author details
1Department of Hepatobiliary Surgery, Air Force General Hospital of PLA,
30 Fucheng Road, Beijing 100142, China. 2Department of Stomatology, Air
Force General Hospital of PLA, Beijing, China.
Received: 23 November 2014 Accepted: 7 April 2015
References
1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic
cancer. Gastroenterology. 2013;144:1252–61.
2. Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J
Gastroenterol. 2014;20:13343–68.
3. Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified
allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol.
2013;980:175–203.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA
Cancer J Clin. 2009;59:225–49.
5. Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M. SnoN/SkiL expression
is modulated via arsenic trioxide-induced activation of the PI3K/AKT
pathway in ovarian cancer cells. FEBS Lett. 2013;587:5–16.
6. Xu K, Chen Z, Qin C, Song X. miR-7 inhibits colorectal cancer cell proliferation
and induces apoptosis by targeting XRCC2. Onco Targets Ther. 2014;7:325–32.
7. Song SD, Zhou J, Zhou J, Zhao H, Cen JN, Li DC. MicroRNA-375 targets the
3-phosphoinositide-dependent protein kinase-1 gene in pancreatic
carcinoma. Oncol Lett. 2013;6:953–9.
8. Li J, Hu GH, Kong FJ, Wu KM, He B, Song K, et al. Reduced STMN1
expression induced by RNA interference inhibits the bioactivity of
pancreatic cancer cell line Panc-1. Neoplasma. 2014;61:144–52.
9. Boyer PL, Colmenares C, Stavnezer E, Hughes SH. Sequence and biological
activity of chicken SnoN cDNA clones. Oncogene. 1993;8:457–66.
10. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of
human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res.
1989;17:5489–500.
11. Pearson-White S. SnoI, a novel alternatively spliced isoform of the ski
protooncogene homolog, sno. Nucleic Acids Res. 1993;21:4632–8.
12. Pearson-White S, Crittenden R. Proto-oncogene Sno expression, alternative
isoforms and immediate early serum response. Nucleic Acids Res.
1997;25:2930–7.
13. Jahchan NS, Ouyang G, Luo K. Expression profiles of SnoN in normal and
cancerous human tissues support its tumor suppressor role in human
cancer. PLoS One. 2013;8:e55794.
14. Imoto I, Pimkhaokham A, Fukuda Y, Yang ZQ, Shimada Y, Nomura N, et al.
SNO is a probable target for gene amplification at 3q26 in squamous-cell
carcinomas of the esophagus. Biochem Biophys Res Commun.
2001;286:559–65.
15. Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, et al. Ski-related novel
protein N (SnoN), a negative controller of transforming growth factor-betasignaling, is a prognostic marker in estrogen receptor-positive breast carcinomas.
Cancer Res. 2003;63:5005–10.
16. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, et al. TGF-beta
induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets
SnoN for degradation. Nat Cell Biol. 2001;3:587–95.
17. Edmiston JS, Yeudall WA, Chung TD, Lebman DA. Inability of transforming
growth factor-beta to cause SnoN degradation leads to resistance to
transforming growth factor-beta-induced growth arrest in esophageal
cancer cells. Cancer Res. 2005;65:4782–8.
18. Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-
promoting complex for ubiquitination and degradation of SnoN. Genes
Dev. 2001;15:2822–36.
19. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback
regulation of TGF-beta signaling by the SnoN oncoprotein. Science.
1999;286:771–4.
20. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski
protooncoproteins are rapidly degraded in response to transforming
growth factor beta signaling. Proc Natl Acad Sci U S A.
1999;96:12442–7.
21. Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA,
et al. A direct intersection between p53 and transforming growth factor
beta pathways targets chromatin modification and transcription repression
of the alpha-fetoprotein gene. Mol Cell Biol. 2005;25:1200–12.
22. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta
signaling. Cell Res. 2009;19:47–57.
23. Jahchan NS, Luo K. SnoN in mammalian development, function and
diseases. Curr Opin Pharmacol. 2010;10:670–5.
24. Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R,
et al. Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol.
2007;27:324–39.
25. Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, et al.
SnoN overexpression is predictive of poor survival in patients with
esophageal squamous cell carcinoma. Ann Surg Oncol. 2008;15:2965–75.
26. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, et al.
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian
cancers: a role in ovarian pathogenesis. Mol Oncol. 2008;2:164–81.
27. Wang N, Wei H, Yin D, Lu Y, Zhang Y, Jiang D, et al. Cyclin D1b overexpression
inhibits cell proliferation and induces cell apoptosis in cervical cancer cells
in vitro and in vivo. Int J Clin Exp Pathol. 2014;7:4016–23.
28. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs.
2000;59:1071–89.
29. Ouaissi M, Silvy F, Loncle C, Ferraz Da Silva D, Martins Abreu C, Martinez E,
et al. Further characterization of HDAC and SIRT gene expression patterns
in pancreatic cancer and their relation to disease outcome. PLoS One.
2014;9:e108520.
30. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic
cancer. Clin Cancer Res. 2000;6:2969–72.
31. Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, et al.
High histone deacetylase 7 (HDAC7) expression is significantly associated
with adenocarcinomas of the pancreas. Ann Surg Oncol. 2008;15:2318–28.
32. Gress TM, Muller-Pillasch F, Geng M, Zimmerhackl F, Zehetner G, Friess H,
et al. A pancreatic cancer-specific expression profile. Oncogene.
1996;13:1819–30.
33. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris
B, et al. Molecular alterations in pancreatic carcinoma: expression profiling
shows that dysregulated expression of S100 genes is highly prevalent.
J Pathol. 2003;201:63–74.
34. Zhang X, Egawa K, Xie Y, Ihn H. The expression of SnoN in normal human
skin and cutaneous keratinous neoplasms. Int J Dermatol. 2009;48:579–83.
35. Villanacci V, Bellone G, Battaglia E, Rossi E, Carbone A, Prati A, et al. Ski/
SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of
Barrett's esophagus. Hum Pathol. 2008;39:403–9.
36. Chia JA, Simms LA, Cozzi SJ, Young J, Jass JR, Walsh MD, et al. SnoN
expression is differently regulated in microsatellite unstable compared
with microsatellite stable colorectal cancers. BMC Cancer. 2006;6:252.
37. Band AM, Laiho M. SnoN oncoprotein enhances estrogen receptor-alpha
transcriptional activity. Cell Signal. 2012;24:922–30.
38. Sarker KP, Wilson SM, Bonni S. SnoN is a cell type-specific mediator of transforming
growth factor-beta responses. J Biol Chem. 2005;280:13037–46.
39. Lamouille S, Derynck R. Oncogene and tumour suppressor: the two faces of
SnoN. EMBO J. 2009;28:3459–60.
Liu et al. Diagnostic Pathology  (2015) 10:30 Page 7 of 740. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, et al. c-Ski
acts as a transcriptional co-repressor in transforming growth factor-beta
signaling through interaction with smads. J Biol Chem. 1999;274:35269–77.
41. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, et al. The Ski
oncoprotein interacts with the Smad proteins to repress TGFbeta signaling.
Genes Dev. 1999;13:2196–206.
42. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology.
2007;7:423–35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
